Anesthesiology and Reanimation Department, 64159Sisli Hamidiye Etfal Training and Research Hospital, Sisli/Istanbul, Turkey.
Ortapedics and Traumotology Clinic, 64159Sisli Hamidiye Etfal Training and Research Hospital, Sisli/Istanbul, Turkey.
Ear Nose Throat J. 2021 Apr;100(2_suppl):174S-179S. doi: 10.1177/0145561320977464. Epub 2020 Dec 1.
To determine taste and smell impairment rates in patients with coronavirus disease 2019 (COVID-19) who were hospitalized in the intensive care unit (ICU).
Between March 2020 and May 2020, patients with COVID-19 hospitalized in the ICU were enrolled in this study. Upon discharge, patients were telephoned and asked to complete a survey related to taste and smell impairment. Characteristics were compared between patients with and without taste and/or smell impairment.
Fifty-two patients were enrolled (mean age, 61.32 ± 12.53 years; mean ICU stay, 10.19 ± 10.24 days). Age, sex, type/number of comorbid diseases, most ICU support modalities, and ICU stay duration did not significantly differ between groups. Patients in group B required more high-flow nasal oxygen therapy than patients in group A ( = .010). In total, 22 (42.3%) of 52 patients experienced taste and/or smell impairment. Three patients experienced isolated smell impairment and one patient experienced isolated taste impairment. Among the 21 patients who experienced smell impairment, 18 (85.78%) experienced hyposmia (mean visual analog scale [VAS] score: 6.33 ± 0.97), while 3 (14.28%) experienced anosmia. Among the 19 patients who experienced taste impairment, 16 (84.22%) experienced hypogeusia (mean VAS score: 6.43 ± 1.03) and 3 (15.78%) experienced ageuisa. Among 22 patients who experienced taste and/or smell impairment, 15 (68.18%) patients (n = 15/22) experienced smell and/or taste impairment before the ICU stay, while 7 (31.82%) patients (n = 7/22) experienced impairment during the ICU stay. Overall, 28.84% (n = 15/52) of the patients experienced taste and/or smell impairment before the ICU stay.
Patients who were hospitalized in the ICU experienced lower rates of taste and/or smell impairment. Some patients experienced taste and/or smell impairment during the ICU stay.
确定在因 2019 年冠状病毒病（COVID-19）住院于重症监护病房（ICU）的患者中的味觉和嗅觉损害率。
2020 年 3 月至 2020 年 5 月，本研究纳入了住院于 ICU 的 COVID-19 患者。患者出院时通过电话进行调查，询问其有关味觉和嗅觉损害的情况。比较了有和无味觉和/或嗅觉损害的患者的特征。
共纳入 52 例患者（平均年龄，61.32 ± 12.53 岁；平均 ICU 住院时间，10.19 ± 10.24 天）。两组间年龄、性别、合并症类型/数量、最常见的 ICU 支持方式和 ICU 住院时间均无显著差异。组 B 的患者需要更多高流量鼻氧疗（ =.010）。共有 52 例患者中的 22 例（42.3%）经历了味觉和/或嗅觉损害。3 例患者仅有嗅觉损害，1 例患者仅有味觉损害。在 21 例嗅觉受损的患者中，18 例（85.78%）患者嗅觉减退（平均视觉模拟量表[VAS]评分：6.33 ± 0.97），而 3 例（14.28%）患者嗅觉丧失。在 19 例味觉受损的患者中，16 例（84.22%）患者味觉减退（平均 VAS 评分：6.43 ± 1.03），3 例（15.78%）患者味觉异常。在 22 例有嗅觉和/或味觉损害的患者中，15 例（68.18%）患者（n = 15/22）在 ICU 住院前就有嗅觉和/或味觉损害，而 7 例（31.82%）患者（n = 7/22）在 ICU 住院期间才出现损害。总的来说，52 例患者中 28.84%（n = 15/52）在 ICU 住院前有嗅觉和/或味觉损害。
住院于 ICU 的患者味觉和嗅觉损害发生率较低。部分患者在 ICU 住院期间出现味觉和/或嗅觉损害。
